Dyslipidemia remains common, but control is rare in Czech adults 25–64
Adults in Czechia are carrying a heavy lipid burden into midlife, and treatment is not closing the gap as effectively as it should. In a cross-sectional analysis of dyslipidemia drawn from the Czech EHES 2019 European Health Examination Survey, investigators assessed lipid status, awareness, treatment, and the degree to which measured values met study-defined normal ranges in adults aged 25–64 years.
The cohort included 1,057 participants, 426 men and 631 women. Across that sample, dyslipidemia emerged as the most common cardiovascular risk factor, affecting 71.7% of the studied population. The lipid abnormalities were broad rather than isolated: 54.3% met the risk threshold for total cholesterol, 52.3% for LDL-C, 41.1% for non-HDL-C, 27.6% for triglycerides, and 8.7% for HDL-C.
The signal is not subtle. Lipid disorders were common, but recognition lagged far behind prevalence.
Awareness lagged behind the measured burden
Only 33.4% of participants with dyslipidemia knew they had the condition. That figure matters clinically because lipid disorders often remain invisible until vascular disease has already progressed, especially when patients feel well and routine care does not include systematic screening or follow-up. In real-world practice, dyslipidemia rarely announces itself with symptoms; it accumulates quietly through endothelial dysfunction, plaque formation, and long-term arterial injury.
Once the condition was identified, treatment still left most patients short of control. Among respondents with known dyslipidemia who were receiving lipid-lowering medication, only 27.7% had their levels corrected to the study-defined normal values. Even within this treated group, the measured lipid profile met the target range in just 23.7% of participants.
Those numbers point to more than a screening problem. They suggest persistent gaps in treatment initiation, titration, adherence, follow-up, or some combination of all three.
The lipid pattern suggests broad residual atherogenic risk
The distribution of abnormal lipid markers matters because atherogenic risk is not captured by a single number. Elevated LDL-C remains the most familiar target, but non-HDL-C and triglycerides provide additional information about remnant particles and overall atherogenic burden, while low HDL-C often tracks with broader metabolic risk. In this cohort, every major lipid compartment except HDL-C showed substantial abnormality rates, indicating that a large share of adults were living with a lipid profile capable of sustaining vascular injury over time.
Cross-sectional data cannot prove causation, and they cannot tell us whether some participants had already improved from worse baseline values. They do, however, show what the population looked like at the moment of measurement. In this case, the snapshot is troubling: high prevalence, low awareness, and limited success in bringing treated patients to normal lipid values.
Why the treatment gap matters in everyday cardiovascular prevention
Midlife is the period when prevention has the most leverage. Atherosclerosis develops over years, not weeks, and lipid exposure during the fifth and sixth decades of life can determine whether a patient enters older age with stable arteries or with the substrate for myocardial infarction, stroke, or peripheral vascular disease. The biology is well established: excess atherogenic lipoproteins infiltrate the arterial wall, trigger inflammatory responses, and promote plaque growth and instability.
In practical terms, failure to identify and lower these lipids early allows cumulative vascular damage to continue unchecked. Statin therapy and other lipid-lowering strategies are designed to interrupt that process, but their benefit depends on recognition, prescription, dose optimization, and sustained use. A treated patient whose values remain outside target range is not a therapeutic success story; it is a reminder that the care pathway stopped too soon.
The study does not include longitudinal event data, so it cannot link the observed lipid profiles directly to future heart attacks or strokes. Even so, the public health implication is hard to miss. A country with a high prevalence of dyslipidemia cannot rely on treatment alone if case finding remains incomplete and goal attainment remains low.
Screening and follow-up may be the weak points
The EHES 2019 design used a stratified random sampling approach and standardized assessment criteria, which strengthens the population-level relevance of the findings. Because the data came from an epidemiological survey rather than a treatment trial, the results reflect ordinary care as it exists in the community. That makes the low awareness rate especially consequential. It means many adults likely move through routine life with undetected lipid abnormalities until another clinical event brings them into sharper focus.
A one-time measurement can also underestimate the complexity of lipid management. Some patients may have limited medication access, some may not tolerate adequate doses, and others may never receive repeat testing after treatment begins. None of those possibilities are measured here, but each could contribute to the modest rate of lipid normalization among treated participants.
The study also offers a reminder that cardiovascular prevention cannot depend on cholesterol numbers alone. Blood pressure, smoking, diabetes, body weight, diet, physical activity, and family history all shape risk. Still, lipids remain a modifiable and measurable target, and this survey suggests that too many adults in Czechia are not reaching it.
A population-level problem with a bedside footprint
For clinicians, the most actionable message sits at the point of care. Lipid disorders are common, awareness is low, and treatment success is incomplete. When a middle-aged patient has no prior diagnosis, normal symptoms, and no obvious reason to be tested, dyslipidemia can still be present and clinically important.
The study leaves open several questions that matter for prevention policy: why awareness remains so low, how often treatment is intensified after an abnormal result, and whether current follow-up systems are adequate to support long-term control. What the data make plain is narrower: in Czech adults aged 25–64, dyslipidemia is widespread, and only a minority of treated patients reach study-defined normal lipid values.